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Tumorigenesis and Neoplastic Progression
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Inflammatory bowel disease (IBD) is a high-risk con-
dition for human colorectal cancer. However, our
mechanistic understanding of the link between in-
flammation and tumorigenesis in the colon is limited.
Here we established a novel mouse model of colitis-
associated cancer by genetically inactivating signal
transducer and activator of transcription 3 (Stat3) in
macrophages, with partial deletion in other myeloid
and lymphoid cells. Inflammation developed in the
colon of mutant mice spontaneously , and tumor
lesions, including invasive carcinoma, arose in the in-
flamed region of the intestine with a frequency similar
to that observed in human IBD patients. The develop-
ment of both inflammation and tumors in the mutant
mice required the presence of microflora. Indeed, in-
flammation was associated with disruption of colonic
homeostasis, fulminant epithelial/tumor cell prolifera-
tion, and activation of the mammalian target of rapa-
mycin (mTOR)-Stat3 pathway in epithelial and tumor
cells. The activation of this pathway was essential for
both the excess proliferation of epithelial/tumor cells
and the disruption of colonic homeostasis in themutant
mice. Notably, a similar abnormal up-regulation of
mTOR-Stat3 signaling was consistently observed in the
colonic epithelial cells of human IBD patients with
active disease. These studies demonstrate a novel
mouse model of IBD-colorectal cancer progression
in which disrupted immune regulation, mTOR-Stat3
signaling, and epithelial hyperproliferation are in-
tegrated and simultaneously linked to the develop-
ment of malignancy. (Am J Pathol 2010, 176:952–967;
DOI: 10.2353/ajpath.2010.090622)
Chronic inflammation in the intestine ranks among the top
three high-risk conditions for colorectal cancer.1 In con-
trast to the other high-risk conditions, the hereditary syn-
dromes of familial adenomatous polyposis and hereditary
nonpolyposis colorectal cancer, in which the genetic pre-
dispositions have been identified, the mechanistic link
between inflammation and tumorigenesis is still largely
unknown.1
IBD is thought to be an unique modulation of the in-
testinal mucosal immune response determined by a com-
plex interplay of genetic, microbial, and environmental
factors.2 Animal models that mimic human IBD and its
associated colorectal cancers have contributed to recent
progress in the understanding of mucosal immunity and
its dysregulation in tumorigenesis.3 A number of widely
used models involve chemically induced inflammation-
associated colorectal cancers, initiated by injecting mice
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with carcinogens such as azoxymethane and/or introduc-
ing chemical irritants such as dextran sulfate sodium.3
Such treatments lead to acute inflammation in the intes-
tine promoted by mucosal damage induced by the chem-
ical, rather than chronic inflammation as observed in
patients with IBD, and therefore may not recapitulate
stochastic events involved in inflammation-associated
cancers in the human.4
An alternative approach is to model IBD by genetic
modifications that favor the development of chronic in-
testinal inflammation. Signaling through interleukin (IL)
10, an anti-inflammatory cytokine, has been targeted,
because evidence indicates that this cytokine is impor-
tant in maintaining the hyporesponsive state of the intes-
tinal mucosa to normal bacterial microflora.5 Sequence
variants or polymorphisms in the IL-10 gene have been
reported to contribute to IBD susceptibility,6–8 indicating
that interference with IL-10 regulation may make an im-
portant contribution to the etiology of IBD. Indeed, inflam-
mation and tumors develop in the colon of IL-10/ mice
in a manner dependent on the presence of intestinal
microflora.9 However, because IL-10 deletion is present
in all cells in these mice, it is difficult in this model to
distinguish effects due to dysregulation of stromal and
immune cells from effects arising from IL-10 mutation in
the epithelium.
To address this issue, attempts have been made to
inactivate IL-10 signaling more specifically in cells of the
immune system. Signal transducer and activator of tran-
scription 3 (Stat3) plays a major role in Janus tyrosine
kinase/Stat signaling induced by IL-10.10 Mice with inac-
tivation of Stat3 targeted by interferon-responsive Mx1-
Cre to multiple types of cells including macrophages and
gut epithelial cells11 or targeted to myeloid cells with
LysM-Cre, developed colitis in the intestine.12 However,
unlike in IL-10/ mice, targeting of Stat3 inactivation in
these mice was not reported to cause tumor forma-
tion,11,12 suggesting that additional factor(s) are required
for prompting tumor development in the colon in the
setting of an inflammatory response. In this regard, al-
though IL-10 plays a major role in myeloid cells, the
cytokine also inhibits activation and function of T cells,
granulocytes, B cells, and natural killer cells,13 although
mice with T lymphocyte-specific depletion of Stat3 did
not develop either colitis or colonic tumors.14
We therefore tested the effect of the conditional inac-
tivation of Stat3flox genes in immune cells using Cre
driven by the colony-stimulating factor-1 receptor pro-
moter.15,16 This inactivated Stat3 in both myeloid and
lymphoid cells, including macrophages, lymphocytes,
and granulocytes, which produced not only a dramatic
inflammatory response of the intestine but also eventual
malignant tumor formation at a frequency similar to that
observed in human IBD patients. These phenotypes were
completely dependent on the intestinal microflora. This
novel mouse model of human IBD recapitulates the in-
creased probability of tumor development in the colon,
an important clinical phenotype in human IBD.1 Further-
more, using this model we present the first evidence that
the inflammation-associated hyperproliferation of colonic
epithelial cells is dependent on the activation of signaling
through an mTOR-Stat3 pathway.
Materials and Methods
Mice
All procedures were conducted in accordance with Na-
tional Institutes of Health regulations concerning use and
care of experimental animals and approved by the Albert
Einstein College of Medicine animal use committee. All of
the mice were housed in the pathogen-free barrier facility
at Albert Einstein College of Medicine.
Stat3-IKO Mice
To establish the transgenic construct for Tg(Csf1r-iCre)jwp,
the improved Cre (iCre) sequence17 was inserted into
ApaI and NotI sites using blunt-ended ligation down-
stream from the colony-stimulating factor-1 receptor pro-
moter.16 The transgenic mice were generated using stan-
dard methods in the Transgenic Mouse Facility at Albert
Einstein College of Medicine. Tg(Csf1r-iCre)jwp mice
were identified by PCR-based genotyping with the follow-
ing primers: F1, 5-CAGGGCCTTCTCCACACCAGC-3;
and F2, 5-CTGGCTGTGAAGACCATC-3. Stat3flox/flox
mice (C57BL/6) were kindly provided by Dr. Colin Stewart
(National Institutes of Health),18 and mice were identified
using a standard PCR-based genotyping procedure with
following primers: F1, 5-GCTGCCAACAGCCACTGC-
CCCAG-3; F2, 5-GAAGGCAGGTCTCTCTGGTGCTTC-
3; and F3, 5-CAGAACCAGGCGGCTCGTGTGCG-3.
The PCR reaction yields a 140-bp product from wild-type,
a 260-bp product from the flox, or a 379-bp product from
the flox-depleted sequence of the Stat3 gene. The mice
used in the experiments were at or more than three
generations of backcrossing to C57BL/6 mice.
Flow Cytometry
Bone marrow-derived macrophages (BMMs) were pre-
pared as described previously with minor changes.19
Antibodies used were R-phycoerythrin- or allophycocya-
nin-conjugated rat anti-mouse F4/80 (Invitrogen, Carls-
bad, CA), R-phycoerythrin-conjugated rat anti-mouse
CD3 (Invitrogen), R-phycoerythrin-conjugated rat anti-
mouse Ly6G (BD Pharmingen, San Diego, CA), PerCP-
conjugated rat anti-CD11b (BD Pharmingen), mouse anti-
mouse Stat3 (IgG2a) (Cell Signaling Technology, Danvers,
CT), and Alexa Fluor 488-conjugated goat anti-mouse
IgG2a. For each reaction, isotopic nonspecific antibody
for the primary antibody and secondary antibody only
controls were used.
Western Blotting Analysis
Western blotting analysis was performed following the
standard procedure. Antibodies were anti-Stat3 (1:2000,
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Cell Signaling), anti--actin (2 ng/ml, Sigma-Aldrich, St.
Louis, MO), and anti-Bcl-xL (1:1000, Cell Signaling).
Human Colon Tissue
Human colon sections from four individuals with active
IBD were provided by the Pathology Department at Mon-
tefiore Medical Center (institutional review board ex-
empted protocol 09-03-096X). The tissue array for human
normal and sporadic colon cancer was from Imgenex
(IMH-359, Imgenex, San Diego, CA).
Histological Analysis
Colons were prepared as “Swiss rolls,” fixed in 10%
formalin, and then paraffin-embedded. Sections were
stained with H&E. The degree of inflammation and tumors
of the colon sections were evaluated by R.S.S., a veteri-
nary pathologist in the Albert Einstein Cancer Center
Histology Core Facility. Inflammation was scored as fol-
lows: 0, no inflammation; 1, minimal; 2, mild; 3, moderate;
4, marked; and 5, severe. Lesions were classified (eval-
uated in regard to the consensus statement of mouse
model of intestinal cancers, with modifications20) as fol-
lows. Hyperplasia was characterized by thickened mu-
cosa with elongated crypts. Crypts consist of goblet cells
and morphologically normal epithelium with nuclear mor-
phology and polarity similar to those of the normal con-
trols. Dysplasia (hyperplasia with dysplasia and inflamma-
tion) was classified by thickened mucosa with elongated,
irregularly branched glands that contain epithelium with
cytological and nuclear atypia including loss of differen-
tiation (goblet cells), polarity, and enlarged nuclei. Areas
of the intestine with inflammation graded as moderate or
greater generally had some degree of dysplasia. Dyspla-
sia was graded in five levels similar to the inflammation
score described above. Carcinoma is distinguished by
tumor cell invasion into submucosa. Specific features
also include the presence of irregular glands, desmopla-
sia, and cell loss as well as multiple invading sites in the
invading mucosa.20 The leukocytic infiltration and injury
scores were determined following the procedure of Xiao
el al.21 For goblet cell identification, tissue sections were
stained with 1% Alcian blue (pH 2.5) and 0.1% neutral
red following standard procedures. For quantitative his-
tological analysis, the stained tissue sections were pho-
tographed to produce TIFF images using an Olympus
IX70 microscope and a Sesicam QEcooled charge-cou-
pled device camera. The entire inflamed colon was pho-
tographed, and at least three mice per group were ana-
lyzed. Positively stained areas were measured and
normalized with the areas of nuclei in the same fields
using ImageJ software as described previously.22 Muco-
sal thickness was measured as the length from the bot-
tom of the crypt to the tip of the gland in TIFF images
using ImageJ. Complete glands of colon sections (ap-
proximately seven per mouse) were measured in the
inflamed region of Stat3-IKO mice and the corresponding
region in Stat3flox/flox mice.
Yellow Fluorescence Protein Detection
Tissue sections from Tg(Csf1r-iCre)jwp.Rosa-YFP mice
were prepared as described previously.22 Sections were
counterstained with 4,6-diamidino-2-phenylindole and
imaged using a Leica SP2 AOBS laser scanning confocal
microscope in the Analytical Image Facility at Albert Ein-
stein College of Medicine. The yellow color of yellow
fluorescence protein (YFP) was converted to green using
Adobe Photoshop.
Immunohistochemistry
Tissues for immunohistochemistry (IHC) experiments
were fixed with 10% formalin, except for those for F4/80
IHC, which were fixed in Zinc fixative (BD Pharmingen),
using standard procedures. Antibodies were 0.1 g/ml
anti-F4/80 (Invitrogen), 3 g/ml anti-CD3 (DakoCytoma-
tion, Carpinteria, CA), 5 g/ml anti-Ly-6G, 1:200 of anti-
Ki-67, 4 g/ml anti-pStat3 (Tyr705), 1:100 for anti-cyclin
D1 (Lab Vision, Fremont, CA), 78 ng/ml anti-CD31 (BD
Pharmingen), 1:50 for anti-pStat3 (Ser-727), 1:400 for
anti-pS6, and 1:400 for anti-Survivin (Cell Signaling). The
standard IHC procedure provided by Cell Signaling was
used.
Antibiotic Treatment
The published procedure for treatment of mice with a
combination of antibiotics (vancomycin, neomycin, met-
ronidazole, and ampicillin [VNMA]) and the detection of
bacteria in stool was used.21 Mice were treated with 10
mg/kg daily Everolimus (Sigma-Aldrich) or 1% dimethyl
sulfoxide/saline for 3 days by gavages.
Results
Stat3 Conditionally Depleted Mice
To determine the effect of blocking Stat3-mediated sig-
naling in macrophages, we established a transgenic
mouse line, Tg(Csf1r-iCre)jwp, in which expression of Cre
was under control of the colony-stimulating factor-1 re-
ceptor promoter (Csf1r or Fms).15,16 An improved Cre
(iCre) sequence, based on mammalian codon usage,17
was used for the transgenic construct to maximize effi-
ciency of target excision. After introduction into FVB em-
bryos, one of three founder mice transmitted the trans-
gene to its offspring, which were phenotypically normal.
The Tg(Csf1r-iCre)jwp transgene was then crossed into
Rosa-26-YFP reporter mice to examine iCre-dependent
deletion at this marker locus. Analysis of Tg(Csf1r-iCre)
jwp/.Rosa26-YFP mice revealed that the YFP signal
was detected only in mice that carried the transgene.
Signal was seen in various tissues, including liver,
spleen, intestine, heart, kidney, and muscle; in each tis-
sue, expression was found in cells with characteristics
consistent with macrophages/dendritic cells (supple-
mental Figure S1A, see http://ajp.amjpathol.org). Consis-
tent with these data, fluorescence-activated cell sorter
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analysis revealed YFP signal in 80% of BMMs (sup-
plemental Figure S1Ba, see http://ajp.amjpathol.org).
However, a YFP signal was also found in 50% of bone
marrow granulocytes and splenic T lymphocytes (Supple-
mental Figure S1Bb and c, see http://ajp.amjpathol.
org). The transgene was then crossed into mice that were
Stat3flox/flox, targeting excision of exons 16 to 21 of the
Stat3 gene, thus inactivating the protein.18 Consistent
with the above data, efficient deletion in Stat3 was ob-
served in BMMs in Tg(Csf1r-iCre)jwp/.Stat3flox/flox mice
(Supplemental Figure S1C, see http://ajp.amjpathol.
org), reducing the level of Stat3 protein in BMMs of these
mice to 20% of that present in BMMs from Tg(Csf1r-
iCre)jwp/.Stat3flox/flox controls (Supplemental Figure
S1D, see http://ajp.amjpathol.org). Fluorescence-acti-
vated cell sorter analysis confirmed efficient Stat3 deple-
tion in BMMs and relatively lower efficiency (50%) in
granulocytes and T or B lymphocytes isolated from
Tg(Csf1r-iCre)jwp/.Stat3flox/flox compared with those
from Stat3flox/flox mice (data not shown). Because Stat3
depletion was found in inflammatory cells rather than in
the intestinal epithelium (described below), Tg(Csf1r-
iCre)jwp/.Stat3flox/flox mice were referred to as Stat3-
IKO. Because no Stat3 depletion was found in Tg(Csf1r-
iCre)jwp/.Stat3flox/flox mice that did not carry the
transgene and they were phenotypically normal, these
were subsequently used as the wild-type control (ie,
Stat3f/f controls).
Development of Spontaneous Colitis in
Stat3-IKO Mice
Stat3-IKO mice (on a mixed background of FVB/C57BL/6
backcrossed for at least three generations to Stat3flox/flox
mice [C57BL/6]) were obtained at the expected Mende-
lian ratio with no abnormalities at birth or within the first
few weeks after parturition (Figure 1A), indicating that
Figure 1. Inactivation of Stat3-induced inflammation in colon. A and B: Mouse size. Stat3-IKO (IKO) and Stat3f/f mice (CON) at 8 (A) and 18 (B) weeks
of age as indicated. C and D: Colon histology. H&E-stained colon sections from a Stat3f/f control (C) or a Stat3-IKO (D) mouse. Scale bar  100 m.
E: Body weight. Stat3-IKO mice were collected between 24 and 29 weeks of age and compared with age-matched Stat3f/f littermates (CON [n  6] versus
IKO [n  5]; unpaired t-test, **P  0.0013). F: Leukocytic infiltration score. The score in the colon of Stat3-IKO and Stat3f/f littermates (unpaired
t-test, **P  0.0021, n  3). G or H: Quantitative analysis of F4/80 or CD3 immunohistochemical analysis, respectively (unpaired t-test, *P  0.0012 for
G and P  0.035 for H, n  3). I–R: Immunohistochemical analysis for infiltrated leukocytes in colon. I–L: Immunochemical analysis for macrophage (M)
(F4/80) for Stat3f/f (I and K) or Stat3-IKO colons (J and L). M–P: Immunohistochemical analysis for T lymphocytes (CD3) for Stat3f/f (M and O) or
Stat3-IKO colons (N and P). The inset in I, J, M, or N is shown in K, L, O, or P in higher magnification, respectively. Q and R: Immunohistochemical
analysis for granulocyte (Ly6G) for Stat3f/f (Q) or Stat3-IKO colons (R). Arrows point to some positive cells. Scale bars: 100m (I, J, M, and N); 30 m
(K, L or O–R).
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inactivation of Stat3 by the transgene did not detectably
alter embryonic or early development. However,20% of
Stat3-IKO mice developed pronounced colitis at 8 weeks
of age, which increased to 50% by 18 to 20 weeks of
age. These mice exhibited persistent diarrhea, bloody
feces, and weight loss. The remaining mutant mice, al-
though without these prominent symptoms, also were
less physically active and had significantly lower body
weights at older ages compared with age-matched
Stat3f/f controls (Figure 1, B and E). Histological analysis
of Stat3-IKO with or without evident colitis revealed in-
creased leukocytic infiltration and intestinal mucosal
thickening compared with Stat3f/f littermates (Figure 1, C
versus D), predominantly in the proximal colon and ce-
cum, without gross histological abnormalities in the small
intestine (data not shown). Consistent with these obser-
vations, the leukocytic infiltration score (degree of leuko-
cytic infiltration and increased mucosal thickness)21 was
significantly higher in the Stat3-IKO colons compared
with control colons (Figure 1F). Twenty of 21 Stat3-IKO
mice aged 8 to 39 weeks developed inflammation in the
colon, whereas only 1 of 21 Stat3f/f controls exhibited a
mild increase in leukocytic infiltration (Table 1, Fisher’s
exact test, P  0.0001).
Macrophages (F4/80 cells) markedly increased in the
colon of Stat3-IKO mice (Figure 1, I and K versus J and
L). There was also a striking increase in CD3 T-cells
(Figure 1, M and O versus N and P) and a moderate
increase in granulocytes (Figure 1, Q versus R). Quanti-
tative analysis by IHC showed a significantly higher den-
sity of F4/80 and CD3 cells in the proximal colon of
Stat3-IKO mice (Figure 1, G and H, respectively). Thus,
inactivation of Stat3 in Stat3-IKO mice was associated
with an inflammatory reaction specifically in the colon.
Tumor Development in Inflamed Colon and
Cecum in Stat3-IKO Mice
Visible polyps were found in the inflamed areas of the
proximal colon (Figure 2A, arrows) and cecum (data not
shown). As with tumors found in human IBD,23 most of the
lesions in Stat3-IKO mice were “flat” with a broad base
(Figure 2C) or morphologically similar to “dysplasia-as-
sociated lesions or masses.”24 Carcinoma was identified
in some of these nodules, with tumor invasion to submu-
cosa or even muscularis external (Figure 2D, arrow). In
addition to its invasion into the submucosa or deeper,
carcinoma was identified by specific features described
in the consensus report and recommendations for pathol-
ogy of mouse models of intestinal cancer.20 These in-
cluded the presence of irregular or angulated glands
with cell loss in invasive components (Figure 2E, ar-
rows), desmoplasia (Figure 2D and Supplemental Fig-
ure S2a and c, see http://ajp. amjpathol.org) and multi-
ple invading mucosa (Supplemental Figure S2c, see http://
ajp.amjpathol.org). Further, cells in invasive glands exhibited
severe atypia with discernible pleomorphism and loss of the
basement membrane (Supplemental Figure S2b and d, see
http://ajp. amjpathol.org). These features are distinct from
hernias of colonic mucosa20 also found in the inflamed
colon and cecum in Stat3-IKO mice (data not shown). In
addition to carcinoma, hyperplasia (Figure 2, H–I) and
dysplasia (Figure 2, J and K) were identified in the in-
flamed intestine in Stat3-IKO mice as described in detail
in Materials and Methods. Neoplastic lesions were found to
be restricted to inflamed areas of the colon or cecum, with
63% of 8- to 39-week-old Stat3-IKO mice exhibiting dyspla-
sia and 16% of Stat3-IKO mice developing carcinoma (Ta-
ble 1). None of the age-matched Stat3f/f controls developed
dysplasia or carcinoma, a highly significant difference be-
tween the groups (Fisher’s exact test, P  0.0001). The
dysplastic lesions were further graded 1 to 5 in regard to
tumor progression, as described in Materials and Methods.
There was a significant positive correlation between the
grade of dysplasia and the degree of inflammation in the
colon of Stat3-IKO mice (Figure 2L), demonstrating that
colon tumor development in Stat3-IKO mice was closely
associated with the presence of inflammation.
Inflammation and Tumor Development in
Stat3-IKO Colon Are Dependent on the
Intestinal Microflora
Disrupted interaction of the host immune system with the
commensal microflora, a major component of the intesti-
nal microenvironment that contributes to mucosal ho-
meostasis,25 probably contributes to the development of
human IBD.26 To determine whether inflammation and
tumor development in Stat3-IKO mice were dependent
on the intestinal microflora, Stat3-IKO and Stat3f/f control
mice were treated with a combination of antibiotics
(VNMA) to substantially reduce the bacterial content of
the intestinal lumen.21 After 4.5 weeks of continuous ad-
ministration of antibiotics through the drinking water, bac-
terial density in the stool of treated Stat3-IKO mice (Figure
3C) or control mice (not shown) was markedly reduced
compared with that of untreated Stat3f/f (Figure 3A) and
Stat3-IKO mice (Figure 3B). Interestingly, higher density
of bacteria was found in the stool of Stat3-IKO mice than
in that of the Stat3f/f controls, indicating that abnormal
regulation of mucosal immunity may induce changes in
microflora in colon (Figure 3, A versus B). Parallel to this
reduction of bacteria, both inflammation and tumor de-
Table 1. Comparison of Tumor Development in Stat3f/f and Stat3-IKO Mice
Mice (8–39 Weeks) Inflammation No lesion Hyperplasia Dysplasia Carcinoma
Stat3-IKO 20/21 6/19 (32%) 13/19 (68%) 12/19 (63%) 3/19 (16%)
Stat3f/f 1/21 17/17 (100%) 0 0 0
Statistical analysis: Stat3f/f versusStat3-IKO (Fisher’s exact test): inflammation, P  0.0001; tumor development (dysplasia  carcinoma), P 
0.0001.
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velopment in the colon of VNMA-treated Stat3-IKO mice
were significantly inhibited (Table 2). There was a notable
lack of inflammation and reduction of mucosal thickness
in the colon of VNMA-treated Stat3-IKO mice (Figure 3, E
versus F), and the histopathology of the colonic mucosa
of these mice was similar to the untreated Stat3f/f controls
(Figure 3, D versus F). The leukocytic infiltration score
and the infiltration of both macrophages and T lympho-
cytes were also markedly reduced (Figure 3, G–J, K, and
N). However, compared with those in untreated Stat3f/f
control mice, infiltrated macrophages in the VNMA-
treated Stat3-IKO mice were still significantly higher (Fig-
ure 3M, CON versus IKO), indicating that the treatment
did not completely inhibit inflammation in the colon. The
injury score, measured by the extent of loss of goblet
cells in the crypt,21 was also consistently significantly
higher in VNMA-treated Stat3-IKO colon compared with
the Stat3f/f control colon (Figure 3L, CON versus IKO).
Parallel to the reduction of inflammation, the development
of colonic tumors was significantly reduced by antibiotic
treatment: no tumors were found in any of the 11 Stat3-IKO
mice from 21 to 27 weeks of age treated with antibiotics,
and only 2 of these treatedmice displayedmild inflammation
and hyperplasia at the end of the treatment. The tumor inci-
dence was significantly lower than that in untreated Stat3-IKO
mice 27 weeks of age or younger (Table 2, P 0.001). These
data indicate that the inflammation and tumor development in
Stat3-IKO colon was dependent on the intestinal microflora.
Further investigation may reveal the specific species of
bacteria involved. Because a large percentage of Stat3-IKO
at 21 weeks of age has developed dysplasia, the result also
suggests that the reduction in inflammation by antibiotic
treatment may cause a regression of the early stages of
dysplasia and neoplasia (Table 2). However, the low fre-
quency of carcinoma precluded determination of whether
the treatment had an effect on established carcinomas.
Figure 2. Tumors developed in the inflamed colon and cecum in Stat3-IKO mice. A–C: Visible nodules. Gross images of colon (A) from a Stat3-IKO (IKO,
bottom) or a Stat3f/f (CON, top) mouse at 19 weeks of age. The proximal end of the colon from the same Stat3f/f (B) or Stat3-IKO mouse (C). Arrows
in C point to the tumor nodules. D and E: Histology of carcinoma. H&E staining of a nodule found in the inflamed colon of a Stat3-IKO mouse. D: The
colon section with tumor invasion to muscularis externa as indicated. The inset in D is shown in E in higher magnification. The long arrow in D points
to the invasive site and short arrows point to the histology of the colon. Arrows in E indicate cell loss in the invading component of the tumor. Scale
bars: 200 m (D); 30 m (E). F–K: Colon histology. Representative H&E images of colon from a Stat3f/f (F and G) and Stat3-IKO mice (H–K) with
hyperplasia (H and I) and dysplasia (J and K). The area indicated by the arrow in F, H, or J is shown in G, I, or K, respectively, in higher magnification.
Scale bars: 100 m (F, H, or J); 10 m (G, I, or K). L: Correlation between inflammation and tumor development. The severity of the dysplastic lesions
and the degree of inflammation in the colon of Stat3-IKO mice from 9 to 39 weeks of age were plotted as individual points. Nonparametric Spearman
correlation was used for statistical analysis: r  0.8313, P  0.0001.
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Impact of Inflammation on Intestinal
Homeostasis
To explore potential mechanisms by which inflamma-
tion might have promoted tumorigenesis in the intes-
tine of Stat3-IKO mice, we examined the impact of
inflammation on colonic epithelial cell proliferation, ap-
optosis, and differentiation. As noted, there was a
prominent alteration in mucosal thickness of the prox-
imal colon from 120 m in controls to 400 m in
inflamed regions in Stat3-IKO mice (Figure 4A). Co-
lonic stem cells normally reside in the lower crypts,
giving rise to transit-amplifying cells, which migrate
toward the lumen, differentiating along lineages with
specific functions.27 Proliferating Ki-67 stem and tran-
sit-amplifying cells are thus normally restricted to the
Figure 3. Inflammation and tumor development in Stat3-IKO colon is dependent on intestinal microflora. A–C: Bacterial density in stools of an untreated Stat3f/f
(A), untreated Stat3-IKO (B), or a VNMA-treated Stat3-IKO (C) mouse. D–F: The correlated histology of the colon. Scale bar  100 m. Immunohistochemical
analysis for macrophages (F4/80) (G and H) and T lymphocytes (CD3) (I and J). Scale bar (in J for all of the images)  100 m. K: Comparison of leukocytic
infiltration. *Unpaired t-test: IKO versus IKO-T, P  0.005; CON versus IKO-T, P  0.174. L: Epithelial injury score. *Unpaired t-test: IKO versus IKO-T, P  0.019;
CON versus IKO-T, P  0.0013. M: Quantitative immunohistochemical analysis for F4/80. *Unpaired t-test: IKO versus IKO-T, P  0.001; CON versus IKO-T, P 
0.047. N:Quantitative immunohistochemical analysis for CD3. *Unpaired t-test: IKO versus IKO-T, P 0.023; CON versus IKO-T, P 0.29. CON, untreated Stat3f/f;
IKO, untreated Stat3-IKO and IKO-T, VNMA-treated Stat3-IKO mice.
Table 2. Effect of Antibiotic Treatment
Mice Inflammation No lesion Hyperplasia Dysplasia Carcinoma
Stat3-IKO (8–27 weeks) 14/15 (93%) 5/15 (33%) 10/15 (67%) 10/15 (67%) 3/15 (20%)
Stat3-IKO VNMA-treated (21–27 weeks) 3/11 (27%) 9/11 (82%) 2/11 (18%) 0 0
Stat3f/f (8–27 weeks) 1/16 (6%) 16/16 (100%) 0 0 0
Statistic analysis: Fisher’s exact test, two-tailed for inflammation: Stat3-IKO VNMA treated versus untreated, P  0.001; Stat3 IKO VNMA treated
versus Stat3f/f untreated, P  0.55; for tumor development (dysplasia): Stat3-IKO VNMA treated versus untreated, P  0.001; for tumor development
(carcinoma): Stat3-IKO VNMA-treated versus untreated, P  0.175.
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lower half of the gland, as shown in Figure 4B. In the
inflamed areas of the colon in Stat3-IKO mice, Ki-67
cells were found along the entire length of the crypt,
including the uppermost region adjacent to the lumen (Fig-
ure 4C, arrows), demonstrating a persistent proliferation of
colonic epithelium responding to the inflammation. No ob-
vious difference in the death of epithelial cells was found
when the colons of Stat3-IKO mice were compared with
those of Stat3f/f controls (data not shown).
Mature glands of the colon consist of several cell popu-
lations, including goblet cells, which can produce and se-
crete mucin and are amajor component of the epithelium.27
Using Alcian blue/neutral red staining to visualize these
cells, we found a significant decrease in goblet cell density
in the inflamed colon of Stat3-IKO mice compared with
equivalent regions in the Stat3f/f controls (Figure 4, D and F
versus E and G). This finding was confirmed by quantitative
analysis (Figure 4J). Consistent with these data, the injury
score21 was an order of magnitude higher in Stat3-IKOmice
than in controls (Figure 4K), demonstrating perturbed cell
differentiation in the colon of Stat3-IKO mice. The depletion
of goblet cells is interesting in light of the fact that genetic
ablation of this lineage and the mucin they produce
leads to tumor formation associated with an inflamma-
tory response.28,29 In addition, using an antibody that rec-
ognizes the endothelial cell-specific marker, CD31, we ob-
served a markedly increased vessel density in the inflamed
colon in Stat3-IKO mice (Figure 4, H versus I), suggesting
increased angiogenesis in the inflamed tissue. Overall,
these findings indicate a significant alteration of ho-
meostasis of the colonic epithelium within the large
intestine of the Stat3-IKO mice, including a marked
increase in proliferating epithelial cells and a loss of
colonic epithelial differentiation.
Figure 4. The impact of inflammation on epithelial biology. A: Mucosal thickness. The thickness of the colonic mucosa was measured on the images of
H&E stained slides as described in Materials and Methods. CON, Stat3f/f (n  3); IKO, Stat3-IKO (n  5) mice (unpaired t-test, *P  0.0009). B and C:
Epithelium proliferation. Immunochemical analysis for Ki-67 for a Stat3f/f (B) and Stat3-IKO colon (C). Arrows in B indicate Ki-67 cells and in C indicate
Ki-67 cells at the tip of the gland. Scale bar  50 m. D–G: Alcian blue/neutral red-stained colon sections from a Stat3f/f (D and F) and a Stat3-IKO mouse
(E and G). The insets in D or F are shown in higher magnification in F and G. Goblet cells are stained in blue, as indicated by arrows. H and I:
Immunochemical analysis for endothelial marker CD31 for colon sections from a Stat3f/f (H) or a Stat3-IKO mouse (I). Arrows point to some of the
CD31-positive capillaries. Scale bars: 100 m (D and E); 30 m (F–I). J: Quantitative analysis of goblet cell density in colon. The normalized density of
goblet cells in the colon of Stat3f/f (CON) and Stat3-IKO (IKO) mice were plotted (*unpaired t-test, P  0.02, n  3). K: Epithelial injury score. The injury
scores in the colon of Stat3-IKO (IKO) (n  5) and Stat3f/f mice (CON) (n  6) (*unpaired t-test, P  0.011) were measured as described in Materials and
Methods.
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Role of Stat3 and mTOR Signaling in
Tumorigenesis in the Inflamed Colon of
Stat3-IKO Mice
In studies directed to oncogenic pathways that may pro-
mote tumorigenesis in the colon of Stat3-IKO mice, we
found that both Stat3 and mTOR are highly activated in
the epithelial and tumor cells in the inflamed colon. When
the colon of Stat3f/f mice was examined using an anti-
body that recognizes the activated form of Stat3 (phos-
phorylated at Tyr705), colonic epithelium was negative for
activated Stat3 (Figure 5A, black arrows), whereas some
mononuclear stromal cells were positive (Figure 5A, red
arrows). In contrast, colonic epithelial and tumor cells in
Stat3-IKO mice (in which the Stat3 gene remains struc-
turally intact) were positive for nuclear activated Stat3,
with more intense staining in the enlarged nuclei of tumor
cells (Figure 5B, black arrows). In addition to the epithe-
lial cells, a high density of infiltrated mononuclear cells
with activated Stat3 was also observed in the inflamed
colon of Stat3-IKO mice (Supplemental Figure S3, see
http://ajp.amjpathol.org), suggesting that Stat3 is not in-
activated in some subsets of myeloid and lymphoid cells
involved in inflammation. Consistent with constitutive ac-
tivation of Stat3 in colonic epithelium, we observed in-
creased epithelial expression of Stat3 target genes, in-
Figure 5. Activation of Stat3 and mTOR pathways in epithelium of inflamed colon. A–H: Activation of Stat3 pathway. Immunochemical analysis for phosphorylated Stat3
(Tyr705) (A and B). Red arrows indicate phosphorylated Stat3 (pStat3) (Tyr705) positively stained stromal cells and black arrows indicate positively stained intestinal
epithelial or tumor cells. Immunochemical analysis for cyclin D1 (C–F). The inset in C or D is shown in E or F in higher magnification. Arrows in E point to cyclin
D1-positive cells in the crypt area of the normal colon. Immunochemical analysis for Survivin (G and H). Arrows point to Survivin-positive cells. Samples from Stat3f/f
(CON) and age-matched Stat3-IKO mice (IKO) are indicated. Scale bars: 10 m (A and B); 100 m (C and D); 30 m (E–H). I: Western blotting analysis of Bcl-xL
expression in colonic mucosa from Stat3f/f (Con, lanes 1–4) and age-matched Stat3-IKO mice (IKO, lanes 5–8). The same sample was blotted by anti--actin antibody.
J–O: Activation of mTOR in epithelium of inflamed colon. J–M: Immunochemical analysis for pS6 in the colon of a Stat3f/f mouse (J and L) and an age-matched Stat3-IKO
mouse (K andM). The inset in J orK is shown in L orM in higher magnification. Arrow in L points to limited pS6-positive epithelial cells in normal colon. Black arrows
inK point to the inflamed region of colon that contains a high density of pS6-positive epithelial cells and red arrows point to the adjacent less inflamed area that contains
fewer pS6-positive cells. Arrow inM indicates the high density of leukocytic infiltration in the inflamed region of colon. N and O: Immunochemical analysis for pS6 for
colon sections from a Stat3-IKO mouse treated with Everolimus (N) and an untreated Stat3-IKO littermate (O). Arrows point to infiltrated leukocytes. P and Q:
Immunochemical analysis for Ki-67 in colon sections from a Stat3-IKO mouse treated with Everolimus (P) and an untreated Stat3-IKO littermate (Q). Arrows indicate
the high density of leukocytic infiltration adjacent to the colonic glands. Scale bars: 100 m/L (J and K); 30 m (L–Q).
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cluding cyclin D1, Survivin, and BCL-xL, which are
functionally important in driving cell proliferation and sur-
vival as well as neoplastic transformation.30 In the colon
of control mice, cyclin D1 was expressed principally in
the crypt epithelial cells (Figure 5, C and E, arrows),
whereas in Stat3-IKO mice expression was elevated in
the majority of epithelial cells throughout the entire hyper-
plastic gland in inflamed areas of the colon, as well as in
dysplastic regions (Figure 5, D and F) and in carcinoma
(data not shown). Another Stat3 target gene, Survivin, is a
key regulator of mitosis and apoptosis and is tightly reg-
ulated in normal colon.31,32 In the colon of Stat3f/f control
mice, only a few Survivin-positive cells (5 positive cells/
gland) were found in crypts of the colonic glands (Figure
5G, arrows). In contrast, a large increase in Survivin-
positive epithelial cells was evident in the inflamed colon
and tumors of Stat3-IKO mice compared with controls
(50 positive cells/gland) (Figure 5H). Finally, we ob-
served elevated expression of another Stat3-regulated
apoptosis inhibitor, BCL-xL, in the mucosa of the proximal
colon of Stat3-IKO mice compared with that in controls
(Figure 5I). These results suggest that inflammation in
Stat3-IKO mice may promote abnormal proliferation and
survival of colonic epithelial cells through the activation of
Stat3 and associated pathways in these cells.
The serine/threonine kinase mTOR is a key effector for
many cellular pathways, and dysregulation of mTOR sig-
naling has been found in various human cancers.33 To
determine whether abnormal activation of mTOR was
induced in the inflamed intestine in Stat3-IKO mice, we
examined the phosphorylation of S6 ribosomal protein
(Ser-235/236) (pS6), which is catalyzed by S6 kinase in a
mTOR-dependent manner.34 Few pS6-positive epithelial
cells were found in normal colon, whereas strong expres-
sion of pS6 was found in colonic epithelial cells in the
inflamed region of Stat3-IKO colon (Figure 5, J and L
versus K and M). This elevated expression of pS6 was
restricted to areas with a high density of leukocytic infil-
tration (Figure 5K, black arrows), whereas very few pS6-
positive cells were found in adjacent areas with milder
infiltration (Figure 5K, red arrows).
To determine whether the activation of mTOR was
functionally linked to the disruption of colonic homeosta-
sis in the inflamed colon, Stat3-IKO and Stat3f/f mice (9 to
12 weeks of age) were treated with 10 mg/kg/day Everoli-
mus for 3 days. Everolimus is a derivative of rapamycin
and a specific inhibitor of mTOR complex 1, the complex
responsible for mTOR-dependent phosphorylation of
S6.33 In Everolimus-treated Stat3-IKO littermates pS6 ex-
pression was at a level similar to that of control Stat3f/f
mice (Figure 5, L versus N), whereas strong expression of
pS6 was observed as expected in regions of leukocytic
infiltration in the colon of untreated Stat3-IKO mice (Fig-
ure 5O), confirming the effectiveness of the inhibitor.
Correlated with the reduced expression of pS6, overpro-
liferation of epithelial cells (measured by Ki-67 expres-
sion) was markedly reduced in the colon of Everolimus-
treated Stat3-IKO mice compared with untreated Stat3-IKO
littermates (Figure 5, P versus Q). Indeed, despite the
prominent leukocytic infiltration that remained in the area
(Figure 5P, arrows), the distribution of Ki-67 cells in the
colon of treated mice was similar to that of normal colon,
and the cells were generally restricted to the lower half of
the gland, as shown in Figure 4B. These results indicate
that the mTOR pathway is activated in inflammation-as-
sociated colonic epithelium and implicate this activation
in the promotion of epithelial cell proliferation.
To confirm the role of inflammation in the activation of
Stat3 and mTOR, we assessed activated Stat3 and pS6 in
Stat3-IKO mice treated with VNMA to remove intestinal
microflora. A marked decrease in both Stat3 activation
and pS6 expression was observed in the colonic epithe-
lial cells of VNMA-treated compared with untreated Stat3-
IKO mice (data not shown).
Regulation of Stat3 Activation in Epithelial Cells
in the Inflamed Colon by mTOR
We next asked whether there was a functional link be-
tween mTOR and Stat3 activation in the inflamed colon.
We observed that Everolimus treatment of Stat3-IKO mice
led to a marked reduction in the activation of Stat3 in
colonic epithelial cells, despite the prominent leukocytic
infiltration that remained in the area (Figure 6A, arrows).
As expected, untreated Stat3-IKO littermates displayed
activated Stat3 in colonic epithelial cells surrounded by
densely infiltrated leukocytes (Figure 6B). This finding
suggests that the activation of Stat3 in inflamed colon
was regulated by the activation of mTOR pathway. To
determine the potential cross-talk between the mTOR
and Stat3 pathways in inflamed colon, we examined the
phosphorylation of Stat3 at Ser-727, an event that can be
mediated by mTOR as well as by the mitogen-activated
protein kinase pathway and is associated with the acti-
vation of the transcriptional regulatory activity of Stat3
toward its target genes.35,36 Nuclear staining of Stat3
phosphorylated at Ser-727 was observed in the colonic
epithelial cells in the inflamed colon of Stat3-IKO mice
(Figure 6D), in a pattern similar to that previously ob-
served for the expression of pS6 and activated Stat3.
Furthermore, treatment with Everolimus markedly re-
duced the phosphorylation of Stat3 at Ser-727 in these
colonic epithelial cells (Figure 6C). These data indicate
that the activation of Stat3 and its downstream factors in
colonic epithelial cells during inflammation-induced tu-
morigenesis is regulated by cross-talk between mTOR
and Stat3.
Abnormal Up-Regulation of mTOR-Stat3 Cross-
Talk in the Colon of IBD Patients with Active
Disease
To determine whether activation of the mTOR signaling
pathway observed in Stat3-IKO mice mimics the inflam-
matory microenvironment in human IBD, the expression
of pS6 in colon samples of four patients with active IBD as
well as 40 human sporadic colorectal cancers was ex-
amined. IHC revealed positive staining of pS6 in the
colonic epithelium in the inflamed colons from each of the
four IBD patients, similar to that observed in Stat3-IKOmice.
Stat3 Inactivation Induces Colon Cancer 961
AJP February 2010, Vol. 176, No. 2
The most intense staining was found in epithelial cells ad-
jacent to areas of dense leukocytic infiltration (Figure 6E). In
contrast, more than 80% of human sporadic colorectal can-
cer samples and normal colonic glands adjacent to the
tumor were negative for pS6 (Supplemental Figure S4, a
and b, see http://ajp.amjpathol.org). Six of 40 human spo-
radic tumor samples displayed a few clusters of pS6-posi-
tive cells in the tumor (Supplemental Figure S4, c and d,
arrows, see http://ajp.amjpathol.org), and the density and
distribution of these positive cells were similar to those
observed in normal mouse colon (Figure 5, J and L). These
data suggest that the activation of mTOR in colonic epithe-
lial cells is specifically induced by inflammation in the colon
of IBD patients. As we observed in Stat3-IKO colons, strik-
ing expression of Stat3 phosphorylated at Tyr-705 and Ser-
727 was found in epithelial cells, often surrounded by prom-
inent infiltration of leukocytes, in the inflamed colon of IBD
patients (Figure 6, F and G). These data indicate that the
both the mTOR and Stat3 pathways, as well as their cross-
talk signaling, are abnormally up-regulated as a result of
inflammation in the inflamed colon of human IBD patients.
Furthermore, our novel mouse model of inflammation-asso-
ciated colorectal cancer closely mimics the abnormal sig-
naling observed in colonic epithelium in IBD.
Discussion
In this study, we establish a novel mouse model of in-
flammation-associated colorectal cancer by inactivation
of Stat3 specifically in hematopoietic cells. Similar to
studies using IL10-deficient mice, this model exhibits the
development of carcinoma as a consequence of inflam-
mation initiated by immune dysregulation leading to mi-
crofloral intolerance, features that mimic human IBD. In
contrast to the IL10 deficiency model, however, the new
model permits us to observe tumor development in a
genetically unmodified colonic epithelium, facilitating
mechanistic studies of tumorigenesis. We have exploited
this aspect of the model to demonstrate a role for mTOR-
Stat3 signaling in inflammation-associated epithelial hy-
perproliferation and the disruption of epithelial ho-
meostasis. Our findings with respect to mTOR and Stat3
activation in human IBD lend further support to the Stat3-
IKO model as a mimic of human disease, as does our
observation of a frequency of malignant progression in
the Stat3-IKO mice similar to that in IBD patients.
Although the pathogenesis of IBD is largely unknown,
dysregulation of mucosal immunity, abrogating the nor-
mal hyporeactive state with respect to the intestinal mi-
croflora, is believed to be the cause of IBD, a high -risk
factor for tumor development.37 Inactivation of IL-10, a
potent anti-inflammatory cytokine, has been closely
linked to the development of IBD in humans.6–8 IL-10
acts as a potent inhibitor of the activation of macro-
phages, monocytes, and dendritic cells13 as well as the
activation and function of natural killer cells and T and B
lymphocytes.13 Stat3 is a major mediator of signaling
downstream of IL-10, as well as that of multiple other cyto-
kines and growth factors.10 Several lines of evidence, in-
cluding a recent genome-wide association study,38,39 sug-
gest that Stat3 plays an important role in human IBD and
inflammation-associated colorectal cancers.40,41 Similar
to mice with IL-10 depletion,9 mice in which Stat3 was
depleted in myeloid cells via LysM- or Mx1 promoter-
driven Cre expression develop colonic inflammation,11,42
indicating that IL-10 plays a critical role in regulating
mucosal immunity in colon and IL-10 exerts its action
through Stat3 expressed in myeloid cells. Mice with Stat3
inactivation in myeloid cells had enhanced Th1 activity
and were highly susceptible to endotoxin shock, with
increased production of inflammatory cytokines.12 We
also found consistently that macrophages isolated from
Figure 6. mTOR-Stat3 cross-talk in human IBD
and Stat3-IKO mouse. A–D: mTOR-Stat3 cross-
talk in epithelial cells of Stat3-IKO colon. A and
B: Immunochemical analysis for phosphorylated
Stat3 (pStat3) (Tyr705) for colon sections from a
Stat3-IKO mouse treated with Everolimus (A)
and a untreated Stat3-IKO littermate (B). C and
D: Immunochemical analysis for pStat3 (Ser-727)
in colon of a Stat3-IKO mouse treated with
Everolimus (C) and a untreated Stat3-IKO litter-
mate (D). E–G: Colon sections from human IBD
patients. Immunochemical analysis for pS6 (E),
pStat3 (Tyr705) (F), and pStat3 (Ser-727) (G).
Arrows pointed to leukocytic infiltration in the
colon sections. Scale bar  30 m.
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Stat3-IKO mice overproduced proinflammatory cyto-
kines, including tumor necrosis factor-, IL-6, and IL-1
and , when treated with the bacterial membrane com-
ponent lipopolysaccharide (data not shown). Inflamma-
tory macrophages are known to produce an array of
cytokines and chemokines that promote infiltration and
activation of other leukocytes, including lymphocytes,
and that also promote angiogenesis, cell proliferation,
and tissue damage.43,44 However, unlike IL-10/ mice,
in which malignant tumors develop in the inflamed intes-
tine,9 no tumors were reported in mice with LysM- or
Mx1-Cre-mediated Stat3 inactivation in myeloid cells. In
contrast, we demonstrate the development of malignancy
in Stat3-IKO mice, suggesting that Stat3 in both myeloid
and lymphoid cells may serve as a control point for the
development of malignant intestinal tumors. Because
mice with T lymphocyte-specific depletion of Stat3 de-
velop neither colitis nor colonic tumors,14 it is possible
that cross-talk among stromal cells is needed for the
promotion of tumorigenesis. Alternatively, differences be-
tween Csf1r and LysM promoter activation of the Cre
recombinase in myeloid cells may account for the en-
hanced tumorigenesis in Stat3-IKO mice. The expression
of LysM is chiefly in mature macrophages and neutro-
phils,45–47 whereas activation of the Csf1r promoter is
initiated at an earlier stage of the myeloid lineage, al-
though the activity in mature granulocytes is weak.16
Thus, the Csf1r promoter may direct Stat3 depletion to a
different and perhaps broader range of myeloid cells
compared with LysM, modulating the function of sub-
populations of myeloid cells involved in tumor develop-
ment. In addition, the difference between these prompt-
ers can be a matter of efficacy.
Although Csf1r-Cre led to a highly efficient inactivation
of Stat3 in bone marrow-derived macrophages, we ob-
served a high density of mononuclear cells with activated
Stat3 among infiltrated stromal cells in the inflamed colon
of Stat3-IKO mice, consistent with observations in human
IBD colons that a large percentage of infiltrated CD68
macrophages and CD4 lymphocytes expressed acti-
vated Stat3.48–50 The subtypes of myeloid and lymphoid
cells in which Stat3 is inactivated or, in contrast, in which
Stat3 is activated in the inflamed colon in Stat3-IKO mice,
has not yet been determined. We anticipate that resolu-
tion of this issue will identify a population of myeloid/
lymphoid cells that plays a key role in regulating ho-
meostasis of mucosal immunity in the colon, with the
consequence that disrupting the function of these cells
initiates inflammation, and that different population(s) of
leukocytes, with intact Stat3 that can respond to cyto-
kines produced at the inflammatory site (eg, IL-6, IL-12,
IL-10, vascular endothelial growth factor, and IL-23 that
signal through Stat350,51), will respond to this cue that
prompts their infiltration into the colon.
Consistent with findings in human IBD and IL-10-defi-
cient mice,2 our study demonstrates that microflora plays
a fundamental role in the development of inflammation in
the colon. The response to antibiotic treatment and the
increased density of bacteria in the stool of Stat3-IKO
mice demonstrate quantitative and possible qualitative
changes in the populations of microflora and reduced
antibacterial ability of the mucosal immune system in this
model. Recent studies have shown that the network of
IL-23, IL-22, and IL-17 plays an important role in mucosal
antimicrobial activities.52,53 On the stimulation of bacteria,
dendritic cells can produce IL-22 directly or indirectly
through activation of Th17 with IL-6 and IL-23 that promotes
the antibacterial activities in the epithelial barrier.52,53
In the normal situation, when the inflammatory stimulus is
removed, IL-10 and transforming growth factor- are be-
lieved to play an immune-suppressive role to resolve the
inflammation.51 Interestingly, most of the cytokines in-
volved in this process, including IL-10, IL-6, IL-23, and
IL-22, mediate their signals through Stat3.51-54. It is possi-
ble that inactivation of Stat3 in certain myeloid/lymphoid
cells in Stat3-IKO mice perturbs this regulation and com-
promises the epithelial barrier, which may induce
changes in the normal populations of microflora and even
lead to expansion of pathogenic bacteria. In addition, the
persistent inflammation, which is often accompanied by
overproduction of various proteinases, reactive oxygen,
and nitrogen, may physically damage the epithelial bar-
rier in Stat3-IKO mice. The potential disruption of the
IL-23/Th17 axis, which was shown to regulate restitution
and repair in intestinal epithelium,51 by Stat3 inactivation
may further enhance the damage of the epithelial barrier
and cause the invasion of pathogenic bacteria. There-
fore, it is likely that interruption of the intestinal epithelial
barrier occurs in the colon of Stat3-IKO mice, which may
promote bacterial translocation into mucosa and submu-
cosa with subsequent infiltration of leukocytes and aug-
mented inflammation.
A large percentage of Stat3-IKO mice developed hy-
perplastic and dysplastic lesions in the colon, with16%
of the mice progressing to invasive carcinoma, a pheno-
type always associated with more extensive inflamma-
tion. Compared with other commonly used mouse mod-
els of inflammation-associated colorectal cancers, the
frequency of carcinoma development in the Stat3-IKO
mice is relatively low, but it is close to the 18 to 20% tumor
incidence in human IBD patients, which is similarly asso-
ciated with prolonged and extensive colitis.55–57 In other
widely used mouse models of chemically induced inflam-
mation-associated colorectal cancer, nearly 100% of
mice develop colon tumors.58–60 Although it is conve-
nient for conducting investigations with these models, the
inflammation is acute, resulting from mucosal damage,
which may not recapitulate stochastic events involved in
inflammation-associated cancers in the human.4 In con-
trast, tumors in Stat3-IKO mice are induced by sponta-
neous chronic inflammation, which may more closely
model the dysregulation of mucosal immunity in the eti-
ology of human IBD.2 The finding that treating Stat3-IKO
mice with antibiotics reduced colonic inflammation, ac-
companied by a similar reduction in early stage tumor
lesions, suggests that inflammation is a causal factor for
the tumor development and persistence in the colon. This
finding is consistent with previous reports that use of
nonsteroidal anti-inflammatory drugs and treatment of
experimental animal models with cyclooxygenase 2 or
nuclear factor-B inhibitors to inhibit inflammation lead to
tumor regression.61–63 Our findings also further demon-
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strate that tumor development in Stat3-IKO mice is
caused by the abnormal mucosal immune response to
microflora, as proposed for the pathogenesis of human
IBD and associated colorectal cancers.2
By specifically targeting Stat3 depletion to the stromal
compartment, the Stat3-IKO model, unlike IL-10-deficient
models, allowed us to demonstrate that genetic distur-
bance of homeostasis in this compartment is sufficient for
inflammation-associated tumorigenesis. Conversely, by
preserving Stat3 function in epithelial cells, we were able
to observe that epithelial Stat3, which is activated in
human tumors associated with inflammation,64–66 was
indeed activated in tumors of Stat3-IKO mice. Stat3 is
persistently active in various human malignancies and
possesses oncogenic potential,30 and the activation of
Stat3 in human colorectal cancer cells is regulated by the
tumor stroma.67 Stat3 can be activated by many cyto-
kines and growth factors commonly produced in inflam-
mation, including IL-6, vascular endothelial growth factor,
colony-stimulating factor-1, IL-23, IL-22, and endothelial
growth factor.30,51,68 Because IL-10 is a potent inhibitor
of the expression of many of these factors in macro-
phages,69 blocking the signal from IL-10 by inactivating
Stat3 in macrophages may promote the overproduction
of these cytokines and lead to inflammation, as observed
in Stat3-IKO mice. As mentioned above, IL-22, which
activates epithelial Stat3, may be overproduced by sev-
eral immune cells when abnormal antibacterial activity is
induced in intestinal mucosa.70 Therefore, multiple fac-
tors in the inflamed colon of Stat3-IKO mice may cause
the persistent activation of Stat3 in epithelial cells. Over-
expression of cyclin D1, Survivin, and Bcl-xL, all targets
of Stat3, was present in the inflamed regions and in
tumors of the Stat3-IKO mice. The expression of these
markers has been linked to abnormal cell proliferation
and survival and subsequent phenotypes of malignant
transformation,32,71–73 further demonstrating the signifi-
cance of Stat3 activation in tumorigenesis in colon and
supporting the hypothesis that overproliferation of colonic
epithelial cells observed in Stat3-IKO colon is due to the
activation of the Stat3 pathway in these cells. The impor-
tance of Stat3 in tumor development in an inflammatory
microenvironment of the intestine is emphasized by re-
cent studies using dextran sulfate sodium-induced coli-
tis/tumor mouse models with targeted inactivation of
Stat3 in intestinal epithelial cells.74,75 The dichotomy be-
tween the potential beneficial effects of inactivating Stat3
in tumor epithelial cells and stimulation of an inflammatory
response by inactivation in the stroma would have to be
considered in therapeutic strategies that have been sug-
gested for targeting Stat3.76–78
mTOR is a critical effector regulating cell growth and
dysregulation of this pathway has been found in many
human diseases, including type II diabetes and various
malignancies.33,79–81 However, a role for mTOR in in-
flammation-associated tumorigenesis has not previously
been demonstrated, and mTOR activation has not been
described in inflamed colonic epithelium either in animal
models or in human disease. It is therefore notable that
mTOR activation, dependent on the presence of intestinal
microflora, is a prominent feature of inflammation-associ-
ated epithelium in Stat3-IKO mice, and that epithelial
hyperproliferation is mTOR-dependent. It is possible that
these unique features of the Stat3-IKO model are related
to our observation of inflammation-dependent malig-
nancy in these mice.
Aberrant activation of mTOR in cancer is probably due
to deregulation of factors that regulate mTOR activity,
because activating mutations in mTOR have not been
identified.82 Signaling through extracellular signal-regu-
lated kinase has been implicated in the activation of
mTOR in human tumors,83 and activation of mitogen-
activated protein kinase/extracellular signal-regulated ki-
nase, linked to tumor necrosis factor- signaling, has
been noted in the inflamed mucosa of IBD patients.84
However, mTOR activation has not previously been de-
scribed in this setting. Our findings demonstrate that
mTOR activation is not a general feature of human colo-
rectal tumors but is present in IBD and is specifically
localized to inflammation-associated epithelium, thus
paralleling our observations in Stat3-IKO mice. These
data provide strong support for the utility of the Stat3-IKO
model in the investigation of inflammation-associated
tumorigenesis.
The cross-talk between mTOR and Stat3 is important in
several physiological and malignant conditions, including
myelin-associated inhibitor-promoted differentiation of
neural progenitors,85 the maintenance of the viability of
breast cancer stem-like cells,86 AKT-enhanced prolif-
eration of human glioblastomas,87 and IL-6-induced
hepatic insulin resistance.88 Here we provide evidence
that mTOR acts as an upstream regulator for the acti-
vation of Stat3 in epithelial cells in the inflamed region
of both human IBD and Stat3-IKO colons. Further stud-
ies of the interaction between mTOR and Stat3 signal-
ing are therefore a promising approach for the eluci-
dation of mechanisms of tumorigenesis in the inflamed
intestine.
The factors that generate mTOR-Stat3 activation in
epithelial cells in response to inflammation in Stat3-IKO
mice have not been determined. A recent study in an
irritant-induced colitis model provided evidence for IL-6
as a link between inflammation and Stat3 activation.74
The authors did not observe a dependence of mTOR
activation on IL-6. It is possible that Stat3 activity repre-
sents the combined effect of IL-6 and a parallel pathway,
yet to be determined, that regulates mTOR. Alternatively,
because IL-6 is capable of up-regulating mTOR signal-
ing88, the role of mTOR as an IL-6 effector may be de-
pendent on the model studied. Future studies will be
directed to the elucidation of factors governing the acti-
vation of these pathways in the inflamed colon. Although
the etiology of IBD is not clear, interaction of the intestinal
microflora with the gut immune system probably plays an
important role.2,89,90 The data presented here suggest
that the novel model established in this study mimics the
modulation of the intestinal mucosal immune response by
a complex interplay of genetic, microbial, and environ-
mental factors in human IBD and points to mTOR as a
potentially key mediator of these interactions.
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